Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia
dc.contributor.author | Santinga, John T. | en_US |
dc.contributor.author | Rosman, Howard S. | en_US |
dc.contributor.author | Rubenfire, Melvyn | en_US |
dc.contributor.author | Maciejko, James J. | en_US |
dc.contributor.author | Kobylak, Lester | en_US |
dc.contributor.author | McGovern, Mark E. | en_US |
dc.contributor.author | Behounek, Bruce D. | en_US |
dc.date.accessioned | 2006-04-10T18:29:27Z | |
dc.date.available | 2006-04-10T18:29:27Z | |
dc.date.issued | 1994-06 | en_US |
dc.identifier.citation | Santinga, John T., Rosman, Howard S., Rubenfire, Melvyn, Maciejko, James J., Kobylak, Lester, McGovern, Mark E., Behounek, Bruce D. (1994/06)."Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia." The American Journal of Medicine 96(6): 509-515. <http://hdl.handle.net/2027.42/31935> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6TDC-4CMYW8C-MJ/2/c143644fa1482494b1097b7ab2c7887b | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31935 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8017448&dopt=citation | en_US |
dc.description.abstract | Elevated cholesterol levels are a major risk factor for coronary heart disease, which remains a significant problem in patients beyond age 65 years. Because drug therapy for the control of hypercholesterolemia in elderly patients is frequently considered to be indicated, we investigated the efficacy and safety of pravastatin in the treatment of elderly subjects with primary hypercholesterolemia. In this 96-week, multicenter, double-blind, placebo-controlled study, 142 subjects (95 women, 47 men) 64 to 90 years of age with elevated cholesterol levels despite dietary intervention were randomized to receive pravastatin 20 mg at bedtime or matching placebo (2:1). Dosage could be doubled after 8 weeks, a bile acid-binding resin could be added after 16 weeks, and nicotinic acid or probucol could be added after 32 weeks, as needed, to adequately lower the low-density lipoprotein cholesterol (LDL-C) levels. Significant reductions in the levels of LDL-C (-30.9%), total cholesterol (Total-C; -21.9%), and triglycerides (TG; -16.7%) and significant increases in the levels of high-density lipoprotein cholesterol (HDL-C; 11.3%) were noted in the group receiving pravastatin treatment at 16 weeks (P In this study, pravastatin was well tolerated and effective in lowering LDL-C, Total-C, and TG and in raising HDL-C during long-term treatment of elderly patients with primary hypercholesterolemia. | en_US |
dc.format.extent | 883129 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Family Medicine and Primary Care | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Geriatric Medicine, University of Michigan Hospitals, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, Sinai Hospital of Detroit, Detroit, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, Sinai Hospital of Detroit, Detroit, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA | en_US |
dc.contributor.affiliationother | Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA | en_US |
dc.contributor.affiliationother | Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA | en_US |
dc.identifier.pmid | 8017448 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31935/1/0000888.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0002-9343(94)90090-6 | en_US |
dc.identifier.source | The American Journal of Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.